DaVita Reports Q3 Results, $62 Million China Impairment

DaVita reported a $62 million non-cash impairment tied to China, with a $27 million net income impact. It repurchased $111 million of shares in Q3 and a further $87 million after Sept. 30. U.S. treatment volume rose 0.1% quarter over quarter; normalized non-acquired growth was 0.4% year over year.